

MEDIA UPDATE – GERMAN VERSION

Novartis opens Kundl/Schaftenau site for life science companies - BASF is the first external company to settle here

- *Novartis opens its Kundl/Schaftenau campus and establishes an attractive research and production location for companies from the life sciences sector*
- *BASF, an important player in the biotechnology and enzyme industry, is the first external company to settle at the Life Science Park and will invest in the production of bacterial enzymes.*
- *Novartis has 75 years of experience in biotechnology in Tyrol - from antibiotics to modern biologics and cell and gene therapies - and continues to invest in the Kundl/Schaftenau campus*

Kundl, 3. Mai 2021 — Novartis is further developing its campus in Kundl/Schaftenau by attracting companies from the life sciences sector. An attractive research and production location is being created that benefits from excellent, competitive production conditions in the heart of Europe and the immediate proximity to Switzerland, Italy and Germany.

For the companies located there, the Life Science Park offers comprehensive and high-quality services in the areas of facility management, energy supply, engineering, maintenance, logistics and environmentally friendly wastewater treatment, as well as the opportunity to concentrate fully on their core business.


"Tyrol is a key location for our production network. Our investments at the Kundl/Schaftenau campus reinforce our commitment to the region: for example, we recently announced the expansion of Kundl into a centre of excellence for nucleic acid production and the entry into COVID-19 vaccine production," says Steffen Lang, Head of Novartis Technical Operations and member of the Novartis Executive Committee. "With the further development into a Life Science Park, we are sending another positive signal for the industrial location."

This is to be further strengthened by the settlement of additional companies, as Mario Riesner, Managing Director of Novartis Kundl/Schaftenau, emphasises: "By opening up the area, Novartis is enabling companies to settle here that can benefit from each other. This creates an extremely diverse industrial location that has great potential for creativity and innovation and brings even more added value to Tyrol."

BASF becomes part of the Life Science Park

BASF is the first external company to become part of the Life Science Park and at the same time an important player in the enzyme and biotechnology industry. BASF will invest in a world-scale plant for the production of bacterial enzymes and thus further expand the production of enzymes and biotech products at the site.

"The cooperation agreement with Novartis is a clear sign of our commitment to the enzymes and biotechnology industry. We will further strengthen our position in the market for enzymes, as the Kundl site has 75 years of biotechnology experience and a corresponding infrastructure



with great know-how," explains Michael De Marco, Vice President Global Business Management Enzymes BASF. "Through our investment and strong integration into the life science park, we will further expand our footprint in biotechnology."

The start of production is planned for 2024. "Together with BASF, we plan to sustainably strengthen our site and thus also create additional jobs", says Mario Riesner.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at <https://www.novartis.com>.

About Novartis Austria

We are reimagining medicine - at the pulse of society, in the heart of Austria. The Austrian Novartis Group is one of the country's leading pharmaceutical companies and is divided into the business areas innovative medicines (Pharmaceuticals, Oncology) and generics (Sandoz). Our employees live our mission every day: to improve and prolong people's lives. With our medicines, we reach 5 million domestic patients. The Tyrolean Novartis sites Kundl/Schaftenau are part of the company's global network of research and development centres. For more information, please visit www.novartis.at

###

Rückfragehinweis

Mag. Julia Ager-Gruber

Communications Lead Campus Kundl/Schaftenau
+43 1 86657-0
novartis.austria@novartis.com

Mag. Sabine Boschetto

Head Country Communications Novartis Austria
+43 1 86657-0
novartis.austria@novartis.com